全文获取类型
收费全文 | 75141篇 |
免费 | 4286篇 |
国内免费 | 2551篇 |
专业分类
耳鼻咽喉 | 617篇 |
儿科学 | 1642篇 |
妇产科学 | 1037篇 |
基础医学 | 8394篇 |
口腔科学 | 1655篇 |
临床医学 | 7120篇 |
内科学 | 9323篇 |
皮肤病学 | 850篇 |
神经病学 | 3929篇 |
特种医学 | 1644篇 |
外国民族医学 | 10篇 |
外科学 | 6385篇 |
综合类 | 13992篇 |
现状与发展 | 4篇 |
一般理论 | 4篇 |
预防医学 | 6692篇 |
眼科学 | 1201篇 |
药学 | 6246篇 |
112篇 | |
中国医学 | 8153篇 |
肿瘤学 | 2968篇 |
出版年
2023年 | 1093篇 |
2022年 | 1681篇 |
2021年 | 2709篇 |
2020年 | 2490篇 |
2019年 | 2643篇 |
2018年 | 2292篇 |
2017年 | 2152篇 |
2016年 | 2028篇 |
2015年 | 1819篇 |
2014年 | 4342篇 |
2013年 | 3947篇 |
2012年 | 3994篇 |
2011年 | 5031篇 |
2010年 | 4518篇 |
2009年 | 3597篇 |
2008年 | 3483篇 |
2007年 | 3879篇 |
2006年 | 3525篇 |
2005年 | 3223篇 |
2004年 | 2662篇 |
2003年 | 2529篇 |
2002年 | 1923篇 |
2001年 | 1720篇 |
2000年 | 1540篇 |
1999年 | 1456篇 |
1998年 | 1239篇 |
1997年 | 1065篇 |
1996年 | 795篇 |
1995年 | 967篇 |
1994年 | 844篇 |
1993年 | 616篇 |
1992年 | 539篇 |
1991年 | 427篇 |
1990年 | 328篇 |
1989年 | 289篇 |
1988年 | 277篇 |
1987年 | 222篇 |
1986年 | 210篇 |
1985年 | 454篇 |
1984年 | 439篇 |
1983年 | 344篇 |
1982年 | 384篇 |
1981年 | 375篇 |
1980年 | 357篇 |
1979年 | 307篇 |
1978年 | 279篇 |
1977年 | 247篇 |
1976年 | 184篇 |
1975年 | 110篇 |
1974年 | 108篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
熊磊教授以理脾为本,将治痰贯穿始终。根据小儿脾常不足、肾常虚、肝常有余的生理特点,癫痫发作期治疗主以涤痰开窍,辅以理气健脾,同时配合活血化瘀通窍与平肝息风潜阳。主要选方为柴芍温胆汤、天麻钩藤饮、桃红四物汤加减;缓解期则以补肾养肝为主,兼以健脾化痰,主要选方为杞菊地黄丸合定痫丸加减,取得较好临床疗效。 相似文献
2.
3.
Defining con-founders that affect the reliability of diagnostic tests for coronavirus disease 2019 is vital to breaking the chain of infection. The elderly population is a higher risk group for the emerging virus. However, gender seems to exert a critical role in modifying the infection risk among women owing to hormonal changes. The menopause transition is an exceptional period for older women where the protective and immunomodulatory effects of the estrogen hormone are lost. Accordingly, attention should be given to postmenopausal women since they will have an increased risk compared to their pre-menopausal peers. 相似文献
4.
5.
6.
7.
8.
《Clinical microbiology and infection》2022,28(8):1120-1125
ObjectivesOur aim was to evaluate the effect of the updated European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group 2019 definitions for invasive pulmonary aspergillosis (IPA) on patient classification and the related all-cause 12-week mortality.MethodsIn this retrospective cohort study from our tertiary care centre, we reclassified patients with haematological malignancy who underwent bronchoalveolar lavage between 2014 and 2019 for suspected IPA using the novel EORTC 2019 criteria. We performed receiver operating characteristic curve analysis to define the optimal cut-off for positive PCR and galactomannan and present survival analyses and their possible association with these diagnostic criteria through post hoc comparisons with log rank and Cox regression.ResultsFrom 323 episodes of suspected IPA in 282 patients, 73 were reclassified: 31 (42.5%) from possible to probable IPA, 5 (6.8%) from EORTC criteria not met to probable IPA, and 37 (50.7%) from EORTC criteria not met to possible IPA. Probable IPA increased therefore 11.1% (64/323, 19.8% to 100/323, 30.9%), mostly due to positive PCR (31/36, 86.1%). There was no difference in mortality between newly defined possible and probable IPA (log rank p = 0.950). Mortality was higher in probable cases with lower cycle thresholds (Ct values) versus higher Ct values (p = 0.004). Receiver operating characteristic curve analysis showed an optimal Ct value cut-off of 36.8 with a sensitivity of 75% (95% CI 64.9%–85.1%) and a specificity of 61.7% (95% CI 53.5–69.9) for 12-week mortality.DiscussionThe new EORTC criteria led to 11.1% more probable IPA diagnoses, mostly due to Aspergillus PCR. Restricting positive PCR to below a certain threshold might improve the discrimination of the new EORTC IPA categories for mortality. 相似文献
9.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
10.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献